The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 32 of the 47 sources its claims cite were checked for support.
Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Open accessAbstract
Background: Alzheimer’s disease (AD) is a debilitating neurodegenerative condition with few treatment options available. Drug repurposing studies have sought to identify existing drugs that could be repositioned to treat AD; however, the effectiveness of drug repurposing for AD remains unclear. This review systematically analyzes the progress made in drug repurposing for AD throughout the last decade, summarizing the suggested drug candidates and analyzing changes in the repurposing strategies used over time. We also examine the different types of data that have been leveraged to validate suggested drug repurposing candidates for AD, which to our knowledge has not been previous investigated, although this information may be especially useful in appraising the potential of suggested drug repurposing candidates. We ultimately hope to gain insight into the suggested drugs representing the most promising repurposing candidates for AD. Methods: We queried the PubMed database for AD drug repurposing studies published between 2012 and 2022. 124 articles were reviewed. We used RxNorm to standardize drug names across the reviewed studies, map drugs to their constituent ingredients, and identify prescribable drugs. We used the Anatomical Therapeutic Chemical (ATC) Classification System to group drugs. Results: 573 unique drugs were proposed for repurposing in AD over the last 10 years. These suggested repurposing candidates included drugs acting on the nervous system (17%), antineoplastic and immunomodulating agents (16%), and drugs acting on the cardiovascular system (12%). Clozapine, a second-generation antipsychotic medication, was the most frequently suggested repurposing candidate (N = 6). 61% (76/124) of the reviewed studies performed a validation, yet only 4% (5/124) used real-world data for validation. Conclusion: A large number of potential drug repurposing candidates for AD has accumulated over the last decade. However, among these drugs, no single drug has emerged as the top candidate, making it difficult to establish research priorities. Validation of drug repurposing hypotheses is inconsistently performed, and real-world data has been critically underutilized for validation. Given the urgent need for new AD therapies, the utility of real-world data in accelerating identification of high-priority candidates for AD repurposing warrants further investigation.
Overview
CoChat Summary
TL;DR
This 10-year literature review of 124 PubMed-indexed Alzheimer’s disease (AD) drug repurposing studies found 573 unique drugs proposed, but no single top candidate emerged and validation was inconsistent. Real-world data was rarely used for validation (5/124, 4%), despite being highlighted as a promising way to prioritize candidates.
Key findings
- Across 124 studies published 2012–2022, 573 unique drugs were suggested for AD repurposing; 65% (370/573) were supported by only one study. Clozapine was the most frequently suggested candidate (N = 6), followed by nine drugs with N = 5: aripiprazole, risperidone, sunitinib, vandetanib, vorinostat, pioglitazone, tamoxifen, verapamil, and adenosine.
- Suggested candidates commonly acted on the nervous system (17%), were antineoplastic/immunomodulating agents (16%), or acted on the cardiovascular system (12%). Within nervous system drugs, antipsychotics (19%), antidepressants (17%), and antiepileptics (15%) represented about half.
- 61% (76/124) of studies performed validation, but only 4% (5/124) used real-world data. Among validated studies, 51% (39/76) had AD-specific validation; experimental studies validated more often (45/48, 94%) than computational studies (31/71, 44%).
- Between 2012–2016, 184 unique prescribable drugs were proposed; between 2017–2022, 482 were suggested, with only 93 drugs overlapping between the two periods.
Methods
- Queried PubMed with a full-text search for “Alzheimer’s” AND “drug repurposing,” limited to May 2012–May 2022; 353 results were manually screened, excluding 72 reviews and 157 out-of-scope articles, leaving 124 studies.
- Extracted repurposing strategy (computational, experimental, or combination), suggested drug candidates, and validation plan; excluded the seven FDA-approved AD drugs from analysis.
- Standardized drug names with RxNorm, mapped to prescribable ingredients, classified drugs using the Anatomical Therapeutic Chemical (ATC) system, and categorized validation as in vitro, in vivo, other, and AD-specific versus non-AD-specific.
Limitations
- The authors state that focusing the literature search on PubMed may have missed AD drug repurposing candidates discussed in journals from other fields, such as computer science (e.g., IEEE journals indexed by Google).
- The authors state that very few studies reported explicitly negative outcomes, suggesting potential selective reporting bias that may have affected results.
- Evident from the text: the broad definition of AD included general repurposing tools and candidates for diseases including but not limited to AD, likely contributing to only about half of validations being AD-specific; the authors also note that lack of comprehensive experimental AD models limited their AD-specific validation analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
18 Valid · 2 Not valid · 8 Not checked · 94 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, we also acknowledge that our analysis of AD-specific validation was limited by the lack of existing comprehensive experimental models for AD (Drummond and Wisniewski, 2017).”
§ Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review > 4.2.1 Alzheimer's-specific validation
What the sources say
- Supportedcites Drummond and Wisniewski, 2017 source
In “Factors to consider when choosing the best model,” the paper states that none of the available models replicate all features of human AD or represent the complete disease. The citing authors’ statement about the limits of their own analysis is their framing; the cited paper supports the attributed point that comprehensive AD models are lacking. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Four of the studies used health insurance claims data (Fang et al., 2021;Xu et al., 2021;Desai et al., 2022;Fang et al., 2022)”
§ Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review > 4.2.2 Limited use of real-world data
What the sources say
- Supportedcites Fang et al., 2021 source
The Methods section (‘Pharmacoepidemiologic validation’) states that Fang et al. used the MarketScan Medicare Claims database, including pharmacy claim data. This confirms that this cited study is one of the studies described as using health insurance claims data; it does not establish the count of four by itself. (LLM, conf=0.94)
- Not matchedcites Xu et al., 2021
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Desai et al., 2022 source
The Methods > Data Source section states that Desai et al. used Medicare fee-for-service claims data from 2007 through 2017. This confirms that the cited study is one of the studies described as using health insurance claims data; this source alone does not establish the total of four. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The limited clinical investigation of antipsychotics in AD may be related to their adverse effects, which include increased risk of cardiovascular and cerebrovascular events,”
§ Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review > 4.1.1 Antipsychotics
What the sources say
- Partly supportedcites Stroup and Gray, 2018 sourceExperimental — accuracy not yet measured
The Abstract says antipsychotics are prescribed off-label for dementia syndromes including Alzheimer’s disease and that adverse effects hamper their utility in those conditions. It does not say that clinical investigation in Alzheimer’s disease is limited or that adverse effects explain a lack of investigation. (LLM, conf=0.82)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“One of the studies failed to validate their initial drug repurposing signal for diseasemodifying antirheumatic drugs (Desai et al., 2022).”
§ Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review > 3.2.2 Real-world data
What the sources say
- Supportedcites Desai et al., 2022 source
The Introduction identifies targeted disease-modifying antirheumatic drugs as repurposing candidates selected for testing. The Conclusions report no difference in dementia risk between the candidate drugs and abatacept, and the Discussion says earlier large signals may have been design artifacts. This supports the claim that the study did not validate the repurposing signal, though its comparison does not establish that the drugs have no effect relative to nonuse. (LLM, conf=0.89)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and one study leveraged data from two large-scale independent EHR databases (Tang et al., 2022).”
§ Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review > 4.2.2 Limited use of real-world data
What the sources say
- Supportedcites Tang et al., 2022 source
The Methods describe analyses using the UCSF EMR and validation using the Mount Sinai EMR. The Patient cohort identification section identifies them as separate databases and reports that the UCSF database alone contains records for over five million patients, supporting the description of two large-scale independent EHR databases. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 5 with their cited sources checked
Create a free account to see all 122 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The long, high-cost, and resource-heavy process of developing AD medications, coupled with their high rate of failure, has led to growing interest in repurposing medications originally designed for other conditions, including cancer, cardiovascular diseases, psychiatric disorders, diabetes, and other neurological diseases.428,429”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [429]
Citations
Cites
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · cited 1×
“Drug repurposing offers several advantages compared to new drug development, including reduced development time frames, lower costs, and importantly, increased assurance of drug safety (Pushpakom et al., 2019), making it an attractive approach for investigating potential AD treatments.”
Background2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014; Yiannopoulou et al., 2019).”
BackgroundAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899 · cited 1×
“While the precise mechanisms of these drugs are largely unknown (Seeman, 2002), they are thought to act primarily on dopaminergic (D2) and serotonergic (5-HT2A) receptors, with additional effects on adrenergic, cholinergic, and histaminergic receptors.”
BackgroundAlzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572 · cited 1×
“(Stroup and Gray, 2018).”
deepDR: a network-based deep learning approach to in silico drug repositioning
Zeng, X., Zhu, S., Liu, X., Zhou, Y., Nussinov, R., & Cheng, F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz418 · Cited by 535 · cited 1×
“For instance, we included studies developing general drug repurposing tools and making predictions for AD (Wu et al., 2013; Croset et al., 2014; Issa et al., 2016; Liu et al., 2016; Jiang et al., 2019; Yu and Gao, 2019; Zeng et al., 2019; Cai et al., 2021; Chen et al., 2021; Tsuji et al., 2021; Muslu et al., 2022), as…”
BackgroundReal-world data: A brief review of the methods, applications, challenges and opportunities
Liu, F., & Panagiotakos, D. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01768-6 · Cited by 496 · cited 1×
“The use of real-world data to investigate drug repurposing signals has become an appealing approach (Xu et al., 2015; Park, 2021; Liu and Panagiotakos, 2022; Zong et al., 2022), particularly in light of the 21st Century Cures Act enacted in 2016, which set forth a framework for use of real-world…”
MethodBrodaty, H., Ames, D., Snowdon, J., Woodward, M., Kirwan, J., Clarnette, R., Lee, E., Lyons, B., & Grossman, F. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0205 · Cited by 464 · cited 1×
“, agitation, hallucinations, and delusions) observed in some individuals with AD, rather than as a potential treatment for AD (Brodaty et al., 2003; Mintzer et al., 2006).”
Background
Research works printed but not linked: 3
- 2022, Anatomical therapeutic chemical (ATC) classification
- 2022, Alzheimer’s association
- 2022, Prescribable RxNorm API - APIs
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01038-3 · Cited by 73
Self-citationCell-type-directed network-correcting combination therapy for Alzheimer’s disease
Li, Y., Serras, C. P., Blumenfeld, J. R., Xie, M., Hao, Y., Deng, E., Chun, Y. Y., Holtzman, J., An, A., Yoon, S. Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.035 · Cited by 73
Poblano, J., Castillo‐Tobías, I., Berlanga, L., Tamayo‐Ordoñez, M. C., Rodríguez‐Salazar, M. D. C., Silva‐Belmares, S. Y., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14055 · Cited by 32
“12,13 This deleterious protein further compromises the integrity of the blood – brain barrier (BBB) by inhibiting vascular endothelial cell proliferation and activating the cyclophilin A-matrix metalloproteinase 9 (MMP9) pathway in peri-cytes.”
Metadata
- Authors
- Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q.
- Affiliations
- Vanderbilt University Medical Center (US)
- Emory University (US)
- Corresponding author
- Grabowska, Monika E.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-09-07
- Volume
- 14
- Pages
- 1257700-1257700
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10512468
- OpenAlex
- W4386502171
- Cited by
- 55
- References
- 53
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 21 · 2023: 1
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Institute on Aging (R01AG065611, R01AG069900, F30AG080885)
- National Institute of General Medical Sciences (T32GM007347, R01GM139891, T32GM152284)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, drug repurposing, clozapine, real-world data, antipsychotic drugs, anticancer agents, immunomodulating agents, cardiovascular drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review. https://app.cochat.ai/papers/10.3389/fphar.2023.1257700
- The paper
- Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023). Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1257700
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.